Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 18, Number 11—November 2012

Letter

Extensively Drug-Resistant Tuberculosis, Central China, 2007–2009

Dawei Shi, Hui Li, Yuling Zhao, Qiong Jia, Christopher Coulter, Liang Li1, and Guofeng Zhu1Comments to Author 
Author affiliations: Institute of Pathogen Biology of Chinese Academy of Medical Sciences, Beijing, China (D. Shi, Q. Jia, G. Zhu); Peking Union Medical College, Beijing (D. Shi, Q. Jia, G. Zhu); National Institute for the Control of Pharmaceutical and Biological Products, Beijing (D. Shi); Henan Provincial Centers for Disease Control and Prevention, Zhengzhou, China (H. Li, Y. Zhao); Pathology Queensland, Brisbane, Queensland, Australia (C. Coulter); and Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing (L. Li)

Main Article

Table

Second-line drug resistance patterns for 143 strains of multidrug-resistant tuberculosis, Henan Province, China, 2007–2009*

Drugs No. (%) strains
INH + RIF 84 (58.7)
INH + RIF + KAN 1 (0.7)
INH + RIF+ CAP 3 (2.1)
INH + RIF + KAN + AMI 1 (0.7)
INH + RIF+ KAN + CAP 1 (0.7)
INH + RIF+ KAN + AMI + CAP 4 (2.8)
INH + RIF+ OFX 31 (21.7)
INH + RIF + OFX + KAN 1 (0.7)
INH + RIF+ OFX + CAP 2 (1.4)
INH + RIF+ OFX + KAN + CAP 3 (2.1)
INH + RIF+ OFX + KAN + AMI + CAP 12 (8.4)
Total 143 (100%)

*INH, isoniazid; RIF, rifampin; KAN, kanamycin; CAP, capreomycin; AMI, amikacin; OFX, ofloxacin.

Main Article

1These authors contributed equally to this article.

TOP